drugset / Trial / NCT00713336

Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval

NCT00713336

Phase 1 Completed 40 enrolled AstraZeneca
RandomizedCrossoverTriple-blindBasic science

Summary

This Study compares two ZD4054 (Zibotentan) doses (10mg and 30mg) with a placebo and a positive control to look at ZD4054 (Zibotentan)'s effect on the ECG of Healthy Volunteer

Timeline

Start
2008-06
Primary completion
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg
Subject Zibotentan Small molecule 10 mg
Subject Zibotentan Small molecule 30 mg

Indications

No indication recorded.